Australian Life Scientist January/February edition out now

In this issue: Lorne 2012; the war on superbugs; microRNAs; streamlining drug development; stem cell therapy; and more.

Staff Writers (Australian Life Scientist)
25 January, 2012 11:39
Comments

Latest issue out now.

The January/February edition of Australian Life Scientist is out now!

In this issue we preview the Lorne 2012 series of conferences, looking at the state of the art in melanoma treatment, what microRNAs are telling us about disease, the increasingly urgent war on superbugs and how drug discovery can be streamlined. We also preview the Australian Neuroscience Society 2012 conference, looking at a stem cell treatment for Hirschsprung’s disease.

To subscribe to Australian Life Scientist and have the magazine delivered to you for only $60/year, go here.

Full contents below:

AusBiotech Viewpoint

Advanced findings for R&D Tax Incentive now open

Under the new R&D Tax Incentive, which commenced on 1 July 2011, provisions for applications for advance findings have been significantly extended, to give companies certainty and guidance – and the process is open now for applications.

Lorne Protein

Flipping cancer’s switch

Dr Nikki Verrills believes reactivating a suppressed protein phosphatase might just switch off leukaemia cells.

Lorne Cancer

Melanoma treatment blasts off

The discovery of a key weakness in metastatic melanoma is a Sputnik moment in the treatment of this deadly cancer. Although Professor Richard Kefford thinks we’re still a long way from landing on the moon.

Lorne Genome

Modelling microRNAs

The humble fruit fly is teaching us how microRNAs seem to be punching above their weight in an ever-growing list of biological functions in health and disease.

Lorne Infection & Immunity

Fighting fire with fire

Resistance to antibiotics is an increasingly serious threat to human health worldwide. Now, a new Wellcome Trust-funded partnership with scientists in Queensland is fighting back.

Lorne Malaria

The right stuff

Drug discovery can be enormously expensive when a drug becomes a disaster. Professor Susan Charman’s team is working to fix potential problems early in the drug-development process.

ANS 2012

Top to bottom

Stem cell therapy has emerged as a promising and potentially curative option for Hirschsprung’s disease, which causes congenital paralysis of the lower colon.